Ireland-incorporated Allergan (NYSE: AGN) has strengthened its dermatology pipeline with the $639 million purchase of US biotech Vitae Pharmaceuticals (Nasdaq: VTAE).
Vitae’s share price shot up by more than 157% to $20.85 on the announcement of the deal, while Allergan’s value also rose by a couple of percent on the promise of the acquired assets.
These include VTP-43742, a Phase II first-in-class, orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze